Development of novel therapies targeting at dysregulated signaling pathways in pulmonary arterial hypertension

VernacularTitle:靶向异常通路的动脉性肺动脉高压新型药物研发
Author: Yidan GAO ^{1
,

2} ; Xuehan JIANG ; Hong ZHANG ; Peiran YANG
Author Information

1. 内蒙古医科大学基础医学院,内蒙古呼和浩特 010110
2. 中国医学科学院基础医学研究所北京协和医学院基础学院生理学系,北京 100005
Keywords: pulmonary arterial hypertension; molecular pathways; ligands and receptors; targeted therapy; drug development
From: Basic & Clinical Medicine 2024;44(8):1088-1093
CountryChina
Language:Chinese
Abstract: Pulmonary arterial hypertension(PAH)is a complex pulmonary vascular disease characterized by pro-gressive elevation of mean pulmonary artery pressure resulted from the pathological feature of pulmonary vascular re-modeling.Without medical intervention,PAH can eventually lead to right heart failure and death of patients.Up to the present,there are few treatment options for PAH are still mainly function through pulmonary vasodilation.Although these treatments can alleviate symptoms,the prognosis remains poor.In recent years,breakthroughs have been made in understanding the pathogenesis of PAH,thus support the development of new treatment strategies tar-geting at dysregulation of signaling pathways in PAH.This review focuses on five critical pathways and the relevant drugs those entered phase Ⅱ clinical trials and discusses their therapeutic potential,so to provide a basis for future research on targeting therapies for PAH patients.